Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

208 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.
Corcoran RB, Settleman J, Engelman JA. Corcoran RB, et al. Among authors: engelman ja. Oncotarget. 2011 Apr;2(4):336-46. doi: 10.18632/oncotarget.262. Oncotarget. 2011. PMID: 21505228 Free PMC article. Review.
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.
Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S. Baba Y, et al. Among authors: engelman ja. Br J Cancer. 2010 Sep 28;103(7):1025-33. doi: 10.1038/sj.bjc.6605846. Epub 2010 Aug 31. Br J Cancer. 2010. PMID: 20808308 Free PMC article.
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.
Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Sequist LV, et al. Among authors: engelman ja. Ann Oncol. 2011 Dec;22(12):2616-2624. doi: 10.1093/annonc/mdr489. Epub 2011 Nov 9. Ann Oncol. 2011. PMID: 22071650 Free PMC article.
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY, Scagliotti GV. Shaw AT, et al. Among authors: engelman ja. Ann Oncol. 2013 Jan;24(1):59-66. doi: 10.1093/annonc/mds242. Epub 2012 Aug 10. Ann Oncol. 2013. PMID: 22887466 Free PMC article.
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Ji F, Jung J, Light M, Lee JS, Debussche L, Sidhu S, Sadreyev RI, Watters J, Engelman JA. Hata AN, et al. Among authors: engelman ja. Oncogene. 2017 Nov 23;36(47):6581-6591. doi: 10.1038/onc.2017.258. Epub 2017 Aug 7. Oncogene. 2017. PMID: 28783173 Free PMC article.
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. Ercan D, et al. Among authors: engelman ja. Oncogene. 2010 Apr 22;29(16):2346-56. doi: 10.1038/onc.2009.526. Epub 2010 Feb 1. Oncogene. 2010. PMID: 20118985 Free PMC article.
Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.
Ebi H, Faber AC, Engelman JA, Yano S. Ebi H, et al. Among authors: engelman ja. Cancer Sci. 2014 May;105(5):499-505. doi: 10.1111/cas.12383. Epub 2014 Mar 26. Cancer Sci. 2014. PMID: 24612015 Free PMC article. Review.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA. Friboulet L, et al. Among authors: engelman ja. Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27. Cancer Discov. 2014. PMID: 24675041 Free PMC article.
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF. Dagogo-Jack I, et al. Among authors: engelman ja. JCO Precis Oncol. 2018;2018:PO.17.00160. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23. JCO Precis Oncol. 2018. PMID: 29376144 Free PMC article.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Koyama S, et al. Among authors: engelman ja. Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501. Nat Commun. 2016. PMID: 26883990 Free PMC article.
208 results
Jump to page
Feedback